$9.43
0.86%
Nasdaq, Oct 22, 04:05 pm EDT. Closed.
ISIN
US0465131078
Symbol
ATRA

Atara Biotherapeutics Inc Stock price

$9.43
+0.50 5.60% 1M
+4.25 82.05% 6M
-8.66 47.87% YTD
-5.20 35.54% 1Y
-23.82 71.64% 3Y
-391.32 97.65% 5Y
-353.07 97.40% 10Y
-256.82 96.46% 20Y
Nasdaq, Closing price Thu, Oct 22 2026
+0.08 0.86%
ISIN
US0465131078
Symbol
ATRA
Industry

Is Atara Biotherapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,102 stocks worldwide.

Key metrics

Basic
Market capitalization
$93.9m
Enterprise Value
$125.5m
Net debt
$31.7m
Cash
$9.9m
Shares outstanding
9.4m
Valuation
P/E
negative
P/S | estimate
15.2 | 34.1
EV/Sales | estimate
20.3 | 45.6
EV/FCF | ex SBC
negative | negative
P/B
negative
Financial Health
Equity Ratio
-190.3%
Return on Equity
-84.9%
ROCE
-86.0%
ROIC
-127.8%
Debt/Equity
-1.1
Share-Based Compensation & Dilution
SBC | % of Revenue
$3.9m | 62.8%
SBC as % of FCF
-
SBC Growth 1Y
-79.8%
Share Count Growth 1Y
35.2%
Shareholder Yield
-35.2%
Financials
Revenue | estimate
$6.2m | $2.8m
EBITDA
$-12.1m
EBIT
$-12.2m
Net Income
$-16.7m
Free Cash Flow | ex SBC
$-21.9m | $-25.8m
Growth
Revenue | estimate
-96.7% | -97.7%
EBITDA
-143.3%
EBIT
-151.9%
Net Income
-387.8%
Free Cash Flow
65.8%
Margin
Gross
91.4%
EBITDA
-194.7%
EBIT
-196.7%
Net
-269.4%
Free Cash Flow | ex SBC
-353.5% | -416.2%
More
EPS
$-1.1
FCF per Share
$-2.3
Short interest
4.4%
Employees
14
Rev per Employee
$8.6m

Atara Biotherapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Atara Biotherapeutics Inc forecast:

8x Buy
80%
2x Hold
20%

Analyst Opinions

10 Analysts have issued a Atara Biotherapeutics Inc forecast:

Buy
80%
Hold
20%

Atara Biotherapeutics Inc Events

Upcoming Event
OCT
29
Q3 2026 Earnings Call
in 7 days
View Past Earnings Reaction

Financial data from Atara Biotherapeutics Inc

Jun '26
+/-
%
6.19 6.19
97% 97%
100%
- Direct Costs 0.53 0.53
99% 99%
9%
5.66 5.66
96% 96%
91%
- Selling and Administrative Expenses 14 14
61% 61%
226%
- Research and Development Expense 4.60 4.60
95% 95%
74%
-12 -12
143% 143%
-195%
- Depreciation and Amortization 0.13 0.13
97% 97%
2%
EBIT (Operating Income) EBIT -12 -12
152% 152%
-197%
Net Profit -17 -17
388% 388%
-270%

In millions USD.

Don't miss a Thing! We will send you all news about Atara Biotherapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Atara Biotherapeutics Inc Stock News

Neutral
Business Wire
●
9 days ago
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that its partner, Pierre Fabre Pharmaceuticals, Inc. (PFP), has received acceptance by the U.S. Food and...
Neutral
Business Wire
●
23 days ago
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today provided an update that its partner, Pierre Fabre Pharmaceuticals, Inc. (PFP), has resubmitted the tabelecleucel B...
Neutral
Business Wire
●
2 months ago
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results for the second quarter 2026 and business updates. “This was an important quarter for At...
More Atara Biotherapeutics Inc News

Company Profile

Atara Biotherapeutics, Inc. operates as a clinical stage company, which engages in the development of novel therapeutics for patients with cancer, autoimmune, and viral diseases. Its pipeline includes Tab-cel, ATA188, ATA2271/ATA3271, and ATA3219. The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in South San Francisco, CA.

Head office United States
CEO Mr. Nguyen
Employees 14
Founded 2012
Website www.atarabio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today